



FOR IMMEDIATE RELEASE

## **Cancer Prevention Pharmaceuticals to Present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018**

### ***Company to highlight progress of Phase 3 trial of lead drug, CPP-1X/sul, for Familial Adenomatous Polyposis***

TUCSON, Arizona, November 19, 2018 – Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that CPP has been invited to give a company presentation at the 30<sup>th</sup> annual Piper Jaffray Healthcare Conference on November 28<sup>th</sup> at 9:10 am at the Palace Lotte Hotel in New York City. CPP Chairman and CEO Jeff Jacob will brief investors on the company's clinical progress.

CPP's lead drug CPP-1X/sul for adults with familial adenomatous polyposis (FAP) is currently in a Phase 3 clinical trial. The FAP-310 clinical trial is a randomized, double-blind, Phase 3 trial designed to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. Final data is expected in the first quarter of 2019. For more information on the clinical trial (CPP FAP-310), please visit: <https://clinicaltrials.gov/ct2/show/NCT01483144>.

FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. Currently there is no effective treatment for FAP. In 2017 the FDA granted "fast-track" status for CPP-1X/sul and previously also granted CPP-1X/sul orphan drug status.

In August 2018, Mallinckrodt Pharmaceuticals signed a license and collaboration agreement through the Mallinckrodt Plc Sucampo AG subsidiary to commercialize CPP-1X/sul combination product, if approved, in North America. This included a \$5 million license fee and CPP is also eligible to receive up to an aggregate of \$185 million, dependent upon achievement of other clinical development and sales milestones, subject to a reduction of up to \$15 million related to amounts provided by Mallinckrodt in advance of entering into this agreement.

#### **About Cancer Prevention Pharmaceuticals, Inc.**

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP's pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the CPP FAP-310 trial, CPP is co-sponsoring with the National Cancer Institute (NCI) and SWOG a large Phase 3 trial in colon cancer survivors. CPP is also working collaboratively with nonprofit groups to support their clinical trials in neuroblastoma, gastric cancer, and early-onset type 1 diabetes. CPP is located in Tucson, Arizona. For more information, please visit [www.canprevent.com](http://www.canprevent.com).



*This press release contains forward looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward looking statements include statements about the continued Phase 3 trial of the CPP-1X/sul therapy. These forward looking statements represent the company's judgment as of the date of this release. The company disclaims, however any intent or obligation to update these forward looking statements.*

**Investor Relations Contact:** Amato and Partners, LLC, Investor Relations Counsel,  
[admin@amatoandpartners.com](mailto:admin@amatoandpartners.com)

**Media Contact:** Christine Brannen, Cancer Prevention Pharmaceuticals, Inc.,  
[press@canprevent.com](mailto:press@canprevent.com), +1.520.908.7774

###